Abstract
Objective To explore the clinical efficacy and safety ofbuspirone combined with paroxetine in the treatment of depression.Methods 76 patients diagnosed as depression according to the diagnostic criteria on the CCMD-3 were randomly divided into study group and control group.Both groups received paroxetine,while the study group received additional buspirone.Hamilton Depression Rating Scale (HAMD) and Treatment Emergent Symptom Scale (TESS) were used for evaluation before treatment and 1,2,4,and 6 weeks after treatment.Results The effectiveness rate was significantly higher in the study group than in the control group (97.3％ vs.89.5％,P＜0.05).The scores on the HAMD was significantly lower in the study group than in the control group 2,4,and 6 weeks after treatment (P＜0.05).There was no significant difference between the two groups in the scores on the TESS (P＞0.05).Conclusions buspirone can enhance the clinical efficacy of paroxetine in the treatment of depression while does not increase the incidence of adverse reactions.It is worth popularizing clinically. Key words: Buspirone; Paroxetine; Depression
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
